case_images: PMC10927992_01
case_images: Sequencing assay showed positive ROS1 fusion and EGFR mutation. (A) Schematic indicating the fusion between the SLC34A2 gene exon 4 and ROS1 gene exon 32. (B) Split-read alignment visualizing the breakpoint of the fusion between SLC34A2 and ROS1 sequences. (C) Sequencing read alignment for EGFR exon 19, showing a potential deletion mutation.
case_images: fonc-14-1357230-g001.jpg
case_images: PMC10927992_01_fonc-14-1357230-g001.jpg
case_images: f1
case_images: Additionally, next-generation sequencing (NGS) examination revealed an ROS1 fusion (SLC34A2) ( Figures 1A, B ) with an abundance of 1.39% and an EGFR exon 19 mutation ( Figure 1C ) with a mutation abundance of 0.61%. The results of the second NGS test were consistent with the previous test results ( Figure 1 ), except for a higher mutation abundance observed in the EGFR mutation (14.38%) and the ROS1 fusion mutation (5.93%).
case_images: CT scan of the patient throughout the whole course of diagnosis and treatment.
case_images: fonc-14-1357230-g002.jpg
case_images: PMC10927992_01_fonc-14-1357230-g002.jpg
case_images: f2
case_images: The detailed diagnosis and treatment process is shown in  Figure 2 .